Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?
NVO's key marketed hemophilia therapies include NovoSeven and Esperoct, which generate incremental revenues for the company. NovoSeven is approved in the United States and the EU for several bleeding disorders, including hemophilia A or B with inhibitors, Factor VII deficiency, and Glanzmann's thrombasthenia. Esperoct is approved for treating Hemophilia A in both adults and children.
Recently, Novo Nordisk's Alhemo was approved in the EU as a once-daily subcutaneous prophylactic treatment for patients aged 12 years or older living with haemophilia A or B with inhibitors. However, the drug is not currently approved in the United States.
NVO is also currently evaluating Mim8 in a late-stage program (FRONTIER) as a prophylaxis treatment for people with hemophilia A with or without inhibitors in patients aged 12 and older. Data readouts from the program have shown superior efficacy of the candidate, along with a favorable safety profile. Based on the findings, Novo Nordisk anticipates submitting Mim8 for regulatory review in 2025. The company is also investigating semaglutide's potential in metabolic dysfunction–associated steatohepatitis (MASH) resolution, expecting to file for regulatory approvals in the United States and the EU in 2025. Subject to approval, these candidates will further contribute to the top line.
Other Pharma Giants Diversifying Beyond Flagship Drugs
Novo Nordisk's arch-rival, Eli Lilly LLY, generates most of its revenues from the sale of its tirzepatide medicines, Mounjaro for T2D, and Zepbound for obesity. However, Lilly also boasts a wide range of products that serve other therapeutic areas, such as neuroscience, oncology and immunology — all high-growth areas and representing significant commercial potential. Some key growth products include the oncology drug Verzenio and immunology drug Taltz, which accounted for 9% and 6% of total first-quarter sales, respectively. Over the past couple of years, LLY's new drugs, including Omvoh and Ebglyss in immunology, Jaypirca in oncology and Kisunla in neuroscience, have all been contributing to its top-line growth. Lilly expects the potential launch of new medicines like imlunestrant for metastatic breast cancer to contribute to growth in 2025.
Another large-cap drugmaker, Merck MRK, is also making significant efforts in broadening its therapeutic reach beyond core revenue drivers. MRK's flagship oncology drug Keytruda, which accounts for nearly half of its total revenues, is expanding its late-stage pipeline to reduce dependence on the product. We believe new products like Capvaxive (pneumococcal vaccine) and Winrevair (PAH drug) have the potential to generate significant revenues over the long term. Merck recently secured the FDA's approval for long-acting RSV antibody Enflonsia for newborns, which is expected to launch later this month.
NVO's Stock Price, Valuation, Estimates
Year to date, Novo Nordisk shares have lost 19.6% compared with the industry 's 0.3% decline. The company has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
NVO Stock Underperforms the Industry, Sector & the S&P 500
Novo Nordisk is trading at a premium to the industry, as seen in the chart below. Going by the price/earnings ratio, the company's shares currently trade at 16.31 forward earnings, which is higher than 15.09 for the industry. However, the stock is trading much below its five-year mean of 29.25.
NVO Stock Valuation
Image Source: Zacks Investment Research
Earnings estimates for 2025 have improved from $3.89 to $3.93 per share over the past 60 days. During the same time frame, Novo Nordisk's 2026 earnings per share estimates have decreased from $4.76 to $4.58.
NVO Estimate Movement
The stock's return on equity on a trailing 12-month basis is 80.95%, which is higher than 33.55% for the large drugmaker industry, as seen in the chart below.
NVO Return on Equity
Novo Nordisk currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novo Nordisk A/S (NVO): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Vancouver Sun
40 minutes ago
- Vancouver Sun
Health Canada approves Ozempic for kidney protection in Type 2 diabetics
Health Canada has approved Ozempic to reduce the risk of further kidney decline among patients with Type 2 diabetes. Between 30 and 50 per cent of people with Type 2 diabetes develop some form of chronic kidney disease. An international clinical trial, called FLOW, showed the risk of kidneys significantly deteriorating or failing was 24 per cent lower in patients taking Ozempic compared to those taking a placebo injection. The patients taking the drug were also less likely to die from cardiovascular disease — another condition that affects many patients with diabetes. Start your day with a roundup of B.C.-focused news and opinion. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Sunrise will soon be in your inbox. Please try again Interested in more newsletters? Browse here. The study, funded by Ozempic manufacturer Novo Nordisk, was peer-reviewed and published in the New England Journal of Medicine last year and contributed to Health Canada's decision. Dr. David Cherney, a nephrologist at Toronto General Hospital, helped lead the Canadian part of the trial and says the results show it's possible to reduce the loss of kidney function before patients need dialysis or a kidney transplant. 'What my patients are scared of is dialysis — dialysis or a transplant,' said Cherney, who is also a senior scientist at the Toronto General Hospital Research Institute, in an interview. 'I can reasonably reduce that risk and thereby reduce their anxiety and fear of serious, serious complications. Not to mention all the cardiovascular disease, which patients are also extremely afraid of.' Dr. Ehud Ur, an endocrinologist in Vancouver who was not involved in the study, said the results are credible and that Health Canada's approval of Ozempic to help prevent kidney decline is 'great news.' 'The prevention of kidney disease is a very important goal in the management of patients with Type 2 diabetes and this is another tool,' said Ur, who is a professor of endocrinology and metabolism at the University of British Columbia. Ozempic is the brand name of an injectable dose of semaglutide, a glucagon-like peptide-1 (GLP-1) hormone. Ozempic was first approved in Canada as a diabetes medication because it reduces blood sugar. It can also decrease appetite and has been approved as a weight-loss drug for people with obesity at a higher dose under the brand name Wegovy, which is also manufactured by Novo Nordisk. In an email, Health Canada confirmed to The Canadian Press that on Aug. 13, it had approved Ozempic 'to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease and cardiovascular death in adults with Type 2 diabetes and chronic kidney disease.' Glomerular filtration rate is a measure that shows how well the kidneys are filtering out waste and excess water. Ozempic is the first GLP-1 drug approved in Canada to protect both kidneys and the heart in patients with Type 2 diabetes, said Ur, noting that the cardiovascular benefits of semaglutide have been extensively studied. 'The benefit of Ozempic is that you also get weight loss, which is a very important goal for most people (with Type 2 diabetes). That's a very exciting combination,' he said. Some people experience gastrointestinal side effects when they take Ozempic, Ur said, including nausea, vomiting, constipation and diarrhea. More severe complications can include gall bladder inflammation and pancreatitis, but most side effects are minor, he said. The benefit of slowing or stopping progressive kidney disease in people with diabetes would outweigh the risks of minor side effects, Ur said. The FLOW trial was conducted in 28 countries, including Canada. The researchers randomized 3,533 people with diabetes and chronic kidney disease to either receive Ozempic or a placebo. The study was conducted between 2019 and early 2024. Participants were followed for an average of 3.4 years to monitor for 'major kidney disease events,' including kidney failure leading to dialysis or transplantation, a 50-per-cent reduction in kidney function measured by glomerular filtration rate, or death from kidney-related or cardiovascular causes. The Ozempic or placebo doses were given to participants on top of other medications they were taking, including drugs to control blood pressure and blood sugar. Although reducing blood pressure and blood sugar have beneficial effects for the kidneys, Cherney said Ozempic appeared to have an additional positive impact on kidney function and future research can help pinpoint how that works. 'Another weapon against kidney disease is incredibly powerful. And these medicines will often turn patients around who are doing very poorly because it addresses so many different issues — the kidney, the cardiovascular, the metabolic, and the weight,' said Cherney. Ur said it's possible Ozempic could play a role in reducing inflammation in the kidneys and that might be one explanation for its positive effect. Regardless of the reason for its effectiveness, he said the FLOW trial and Health Canada's approval reinforces the importance of using the drug 'relatively early in the disease process' to minimize kidney damage in people with Type 2 diabetes. Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content. Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our daily newsletter, Posted, here .
National Post
40 minutes ago
- National Post
Health Canada approves Ozempic for kidney protection in Type 2 diabetics
Glomerular filtration rate is a measure that shows how well the kidneys are filtering out waste and excess water. Ozempic is the first GLP-1 drug approved in Canada to protect both kidneys and the heart in patients with Type 2 diabetes, said Ur, noting that the cardiovascular benefits of semaglutide have been extensively studied. 'The benefit of Ozempic is that you also get weight loss, which is a very important goal for most people (with Type 2 diabetes). That's a very exciting combination,' he said. Some people experience gastrointestinal side effects when they take Ozempic, Ur said, including nausea, vomiting, constipation and diarrhea. More severe complications can include gall bladder inflammation and pancreatitis, but most side effects are minor, he said. The benefit of slowing or stopping progressive kidney disease in people with diabetes would outweigh the risks of minor side effects, Ur said. The FLOW trial was conducted in 28 countries, including Canada. The researchers randomized 3,533 people with diabetes and chronic kidney disease to either receive Ozempic or a placebo. The study was conducted between 2019 and early 2024. Participants were followed for an average of 3.4 years to monitor for 'major kidney disease events,' including kidney failure leading to dialysis or transplantation, a 50-per-cent reduction in kidney function measured by glomerular filtration rate, or death from kidney-related or cardiovascular causes. The Ozempic or placebo doses were given to participants on top of other medications they were taking, including drugs to control blood pressure and blood sugar. Although reducing blood pressure and blood sugar have beneficial effects for the kidneys, Cherney said Ozempic appeared to have an additional positive impact on kidney function and future research can help pinpoint how that works. 'Another weapon against kidney disease is incredibly powerful. And these medicines will often turn patients around who are doing very poorly because it addresses so many different issues — the kidney, the cardiovascular, the metabolic, and the weight,' said Cherney. Ur said it's possible Ozempic could play a role in reducing inflammation in the kidneys and that might be one explanation for its positive effect. Regardless of the reason for its effectiveness, he said the FLOW trial and Health Canada's approval reinforces the importance of using the drug 'relatively early in the disease process' to minimize kidney damage in people with Type 2 diabetes. Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content. Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our daily newsletter, Posted, here.
National Post
2 hours ago
- National Post
Strategic Storage Growth Trust III, Inc. Reports Second Quarter 2025 Highlights
Article content LADERA RANCH, Calif. — Strategic Storage Growth Trust III, Inc. ('SSGT III') announced highlights for the three months ended June 30, 2025. Article content 'The second quarter was highlighted by continued lease up of our non-stabilized portfolio and the acquisition of two premier self-storage facilities,' commented H. Michael Schwartz, President, Chief Executive Officer and Chairman of the Board of Directors of Strategic Storage Growth Trust III, Inc. 'These acquisitions underscore our unwavering focus on growing our portfolio with high-quality properties in strategically advantageous markets.' Article content Key Highlights for the Three Months Ended June 30, 2025: Article content Acquired two high-quality self-storage facilities located in well-populated and high-growth markets. Acquisition of a parcel of land in New Westminster, British Columbia in the Greater Vancouver Area of Canada pursuant to a joint venture with SmartCentres Real Estate Investment Trust. Increased revenues by approximately $3.1 million or 139% for the quarter ending June 30, 2025, vs. the quarter ending June 30, 2024, primarily due to the acquisition of 13 self-storage properties over the last 12 months and the lease up of our non-stabilized properties. Article content Capital Transactions: Article content Acquisitions Article content On June 20, 2025, we acquired a self-storage facility located in Houston, Texas (the 'Houston Property') for a purchase price of approximately $28.5 million. The Houston Property contains approximately 880 storage units and consists of approximately 98,900 net rentable square feet. The acquisition of the Houston property was funded with the assumption of a loan from the seller and a loan from SmartStop as described below. Article content On June 25, 2025, we acquired a self-storage facility located in Vancouver, BC (the 'Vancouver Property') for a purchase price of CAD $36.3 million. The Vancouver Property contains approximately 800 storage units and consists of approximately 52,400 net rentable square feet. The acquisition of the Vancouver property was funded with a loan from SmartStop as described below. Article content On June 10, 2025, our Operating Partnership (through its subsidiaries) and SmartCentres (through its subsidiaries) acquired an undeveloped tract of land located in New Westminster, BC in the Greater Vancouver Area of Canada (the 'New Westminster Land') from an unaffiliated third party. The New Westminster Land is owned by a limited partnership in which we (through our subsidiaries) and SmartCentres (through its subsidiaries) are each a 50% limited partner and each have an equal ranking general partner. At closing, our Operating Partnership (through its subsidiaries) subscribed for 50% of the units of the limited partnership at an agreed upon subscription price of approximately CAD $3.8 million, representing a contribution equivalent to 50% of the purchase price of the New Westminster Land. We expect that the limited partnership will develop the New Westminster Land into a self-storage facility (the 'New Westminster Property') that will contain approximately 99,275 net rentable square feet and 1,170 storage units. Article content Debt Transactions Article content On June 3, 2025, we, through a wholly-owned subsidiaries of our Operating Partnership, entered into a delayed draw mezzanine loan agreement (the 'Delayed Draw Mezzanine Loan Agreement') with SmartStop OP, an affiliate of our sponsor, for up to $25.0 million (the 'Delayed Draw Mezzanine Loan'). The Delayed Draw Mezzanine Loan requires a commitment fee equal to 0.50% of the amount drawn on the loan. In June 2025, we borrowed $16.0 million pursuant to the Delayed Draw Mezzanine Loan. The proceeds of the loan were used to partially fund the acquisition of the Houston Property and the New Westminster Land. The interest rate on the Delayed Draw Mezzanine Loan is a variable rate equal to SOFR plus 3.00% per annum. Payments on the Delayed Draw Mezzanine Loan are interest only for the term of the loan. The initial maturity date is December 31, 2025, with two six-month extension options. The Delayed Draw Mezzanine Loan is prepayable in whole or in part at any time without fees or penalty. Article content On June 20, 2025, in connection with the acquisition of the Houston Property, we, through a special purpose entity formed to acquire and hold the Houston Property, assumed a loan with Aegon USA Realty Advisors, LLC as the lender affiliate responsible for managing and servicing the loan (the 'Aegon Loan') for $18.5 million. The Aegon Loan is secured by a first mortgage lien on the Houston Property. Under the terms of the loan agreement (the 'Aegon Loan Agreement'), the amount outstanding under the Aegon Loan bears interest at an annual fixed rate equal to approximately 4.10%. The Aegon Loan has a maturity date of November 1, 2046. Monthly payments due under the Aegon Loan are interest-only until December 2028, with principal and interest payments due monthly thereafter based on twenty-five year amortization. The loan documents contain: customary affirmative and negative covenants; agreements; representations; warranties and borrowing conditions; reserve requirements and events of default all as set forth in such loan documents. In addition, and pursuant to the terms of the limited recourse guaranty, we serve as a non-recourse guarantor with respect to the Aegon Loan. Article content On June 24, 2025, in connection with the acquisition of the Vancouver Property, we, through a wholly-owned subsidiary of our Operating Partnership, entered into a loan agreement (the 'Vancouver Bridge Loan Agreement') with SmartStop OP, an affiliate of our sponsor, for a $25 million loan (the 'Vancouver Bridge Loan'). The Vancouver Bridge Loan is secured by a pledge of the equity interest in the indirect, wholly-owned subsidiary of our Operating Partnership that owns the Vancouver Property and required a commitment fee equal to 0.50% of the loan amount. The proceeds of the Vancouver Bridge Loan were used to partially fund the acquisition of the Vancouver Property. The interest rate on the loan is a variable rate equal to SOFR plus 3.00% per annum. Payments on the Vancouver Bridge Loan are interest only for the term of the loan. The initial maturity date is December 31, 2025 with two six month extension options. The Vancouver Bridge Loan is prepayable in whole or in part at any time without fees or penalty. Article content In June 2023, in connection with the acquisition of the Toronto Property, we, through a special purpose entity formed to acquire and hold the Toronto Property, entered into a term loan with Bank of Montreal (the 'Bank of Montreal Toronto Loan') for approximately CAD $18.8 million, which is secured by a first mortgage lien on the Toronto Property. Under the terms of the loan agreement (the 'Bank of Montreal Toronto Loan Agreement'), the interest rate is equal to the Compounded Canadian Overnight Repo Rate Average ('CORRA') plus a spread of approximately 2.80%. In addition, we entered into an interest rate swap agreement with a notional amount of approximately CAD $18.8 million and effective date of June 15 ,2023, whereby the CORRA is fixed at approximately 4.50% through June 15, 2026 (the 'Bank of Montreal Toronto Swap'). The Bank of Montreal Toronto Loan had an initial term of two years, maturing on June 15, 2025, with a one-year extension option. On June 16, 2025, we amended the Bank of Montreal Toronto Loan to extend the maturity date by three years to June 15, 2028, and we amended the interest rate swap agreement whereby the CORRA is fixed at approximately 3.35% through June 15, 2028. Article content DST Transactions Article content On August 30, 2024, we, through our subsidiaries, initiated an offering to sell up to a maximum aggregate offering amount of approximately $29.8 million of beneficial interests in Blue Door Property I, DST, a DST ('Blue Door I DST'), to accredited investors in a private offering (the 'Blue Door I DST Offering'). As of June 30, 2025, we have substantially sold out the beneficial interests in Blue Door I DST pursuant to the Blue Door I DST Offering. Article content During June 2025, we commenced an offering (the 'Blue Door II DST Offering') by Blue Door Property Holdings II, LLC, a Delaware limited liability company (the 'Depositor'), to issue and sell up to a maximum aggregate offering amount of approximately $64.8 million of beneficial interests in Blue Door Property II, DST (the 'Blue Door II DST') to investors seeking a like-kind exchange transaction under Section 1031 of the Internal Revenue Code. The Blue Door II DST is comprised of the Orlando Property, Corinth Property, and Pasadena Property that were acquired as part of the Six Property Portfolio. Article content About Strategic Storage Growth Trust III, Inc. (SSGT III): Article content SSGT III is a Maryland corporation that elected to qualify as a REIT for federal income tax purposes. SSGT III's primary investment strategy is to invest in growth-oriented self-storage facilities and related self-storage real estate investments in the United States and Canada. As of August 15, 2025, SSGT III has a portfolio of 10 operating properties in the United States, comprising approximately 8,000 units and 880,600 net rentable square feet; five operating properties in Canada, comprising approximately 3,180 units and 327,000 net rentable square feet; and joint venture interests in three developments in two Canadian provinces (Québec and British Columbia). In addition, a subsidiary of SSGT III serves as the sponsor of two Delaware Statutory Trusts, which currently owns five operating properties in the United States comprising approximately 3,440 units and 472,100 net rentable square feet. Article content About SmartStop Self Storage REIT, Inc. (SmartStop): Article content SmartStop Self Storage REIT, Inc. ('SmartStop') (NYSE:SMA), is a self-managed REIT with a fully integrated operations team of more than 600 self-storage professionals focused on growing the SmartStop® Self Storage brand. SmartStop, through its indirect subsidiary SmartStop REIT Advisors, LLC, also sponsors other self-storage programs. As of August 19, 2025, SmartStop has an owned or managed portfolio of 230 operating properties in 23 states, the District of Columbia, and Canada, comprising approximately 167,200 units and 18.7 million rentable square feet. SmartStop and its affiliates own or manage 44 operating self-storage properties in Canada, which total approximately 39,000 units and 3.9 million rentable square feet. Additional information regarding SmartStop is available at Article content Article content Article content Article content Contacts Article content David Corak Article content Article content Article content Article content
